Systemic lupus erythematosus (SLE) is characterized by various symptoms and multi-organ involvement. Hypophosphatemia has been described in several diseases accompanied with systemic inflammation. However, hypophosphatemia has rarely been described in SLE patients, especially in those without nephritis. We report the case of a 13-year-old girl with SLE who developed hypophosphatemia without renal involvement. Her hypophosphatemia was caused by renal loss of phosphorus and persisted for 7 months. It improved as her complement levels increased. Therefore, hypophosphatemia may be related to disease activity in SLE patients.
Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by various symptoms, such as fatigue, fever, myalgia, and arth ritis, with multi organ involvement. Among the various organs, renal involve ment is significant and can lead to morbidity and mortality 1) . Hypophosphatemia has been reported in several autoimmune disorders, such as Sjögren's syndrome, tumors, and thyroiditis, and also in sepsis 25) . However, it has rarely been described in SLE.
Here, we report a case of hypophosphatemia in a SLE patient without ne phritis, which was caused by the renal loss of phosphorus, it improved as dis ease activity improved.
Case report
A 13yearold girl with myalgia for 1 month was referred to our hospital. A week ago, she was admitted to a local hospital for lethargy and myalgia. One week before admission, she experienced eczema. During admission, mild fever was checked twice, and leukopenia, abnormal liver function, and thrombo cytopenia were found.
On physical examination, her blood pressure was 99/68 mmHg and her pulse rate was 125 beats/min. She showed myalgia, general weakness, oral ulcers, vasculitic lesions on her face, weight loss, and hair loss. She did not have joint pain, photosensitivity, or the Raynaud's phenomenon. There were no signs of renal in volvement, such as proteinuria, hematuria, and azotemia. The initial laboratory findings are shown in Table 1 .
She satisfied 5 of the 11 American College of Rheumato logy 1997 Revised classification criteria for SLE, discoid rash, oral ulcers, leukopenia, positive antidouble stranded deoxyribonucleic acid antibody (antidsDNA) and positive antinuclear antibody (ANA) 6) . Also, a diagnosis of SLE was made by disocoid rash, oral ulcers, hair loss, leukopenia, positive ANA, positive antidsDNA antibody, low comple ment levels and positive direct Coombs' test, fulfilling 8 of the 17 Systemic Lupus International Collaborating Clinics classification criteria for SLE 7) . Her Systemic Lupus Erythe matosus Disease Activity Index (SLEDAI) score was 12.
The treatment was initiated with prednisolone and hydro xychloroquine. Her symptoms gradually improved after treatment, but the complement levels remained low. In addition, hypophosphatemia without hypercalcemia or ab normal level of intact parathyroid hormone was observed. Therefore, we measured the reabsorption of phosphorus from renal tubule.
The tubular reabsorption of phosphorus (TRP) was 89.7 %, which was within the normal range. Also, the ratio of the tubular maximum reabsorption of phosphate to glo merular filtration rate (TmP/GFR) was 1.61 mg/dL, which was extremely low compared with the normal range. A few months after the diagnosis, we started to treat her by oral phosphate replacement and hypophosphatemia was im proved after recovering the normal complement level. Seven months after the treatment, we stopped oral phosp hate replacement and her level of phosphorus became normal.
Twentyone months since starting treatment, she has maintained a normal phosphorus range without replace ment, and the prednisolone dose is being reduced. The treatment and disease course of our patient are shown in Fig. 1 .
Discussion
This case is the first report of hypophosphatemia in SLE patient in Korea. Hypophosphatemia in SLE has rarely re ported. Further, there were no other abnormalities, such as hypomagnesemia, hyponatremia, hypercalcemia, or hyper parathyroidism. Fujiwara et al. reported that hypophosp hatemia in SLE is associated with high serum tumor nec rosis factor α (TNF α) and interleukin 6 levels (IL6) 8) .
Before this report, there had been several reports about cytokine and hypophosphatemia. Zwaveling et al. reported 3, 5) . Recently, Yamazawa et al. reported them in ma crophage activation syndrome 9) . All of them have paid at tention to cytokines, such as TNF α and IL6, as a cause of hypophosphatemia. TNF α is known to affect the reab sorption of sodium, phosphates, uric acid, glucose, and bicarbonates at the proximal tubules 10) . Therefore, hypo natremia, hypouricemia, and metabolic acidosis are ac companied with hypophosphatemia. In our case, however, except for hypophosphatemia, there were no other abnor mal laboratory findings. Therefore, the patient's pathoge nesis was not clear.
Most reports describe cytokines, but unfortunately, we did not investigate the patient's cytokines, which made it difficult for us to describe the pathogenesis of hypophosp hatemia. However, we found that disease activity is asso ciated with hypophosphatemia. As we showed in Fig. 1 , the complement level was correlated with the phosphorus level. It seems that the phosphorus level may suggest dis ease activity in SLE patients.
Hypophosphatemia caused by the renal loss of phosph orus has been described in inherited disorders, such as X linked hypophosphatemia 11) . Renal sodiumphosphate cotransporter is an essential part of these disorders 12) . Fib roblast growth factor 23 is one of the representative genes that regulate this transporter 13) . Recently, sodiumhydrogen exchanger regulatory factor 1 was reported to be a regulator gene 14) . However, as the patient's hypophosphatemia im proved, she could not have had gene mutation. Instead, we can presume that there are unknown substances that affect the cotransporter and that may be related to SLE activity In summary, our case of a 13yearold girl with SLE ex hibited hypophosphatemia, without hypomagnesemia, hyponatremia, hypercalcemia, or hyperparathyroidism. The cause was the loss of phosphorus from the kidney, which was confirmed by TRP and TmP/GFR. Further works involving a large number of patients from a multicenter are needed.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
